A recent analysis published in Clinical Pharmacology and Therapeutics, evaluated current evidence to compare the effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the prevention of stroke in patients with atrial fibrillation. The researchers made an adjusted, indirect comparison based on the results of the RE-LY, ROCKET-AF, and ARISTOTLE trials. They found that apixaban may be the more effective anticoagulant as it has a 55% probability of yielding the highest total lifetime quality adjusted life years (QALYs). Although useful, such studies make many assumptions and therapy should continue to be individualized for each patient.  Which new oral anticoagulant do you see dispensed the most often in your practice?

For more information please see article in WebMD.